Front Burner

Everything you need to know about Pfizer's COVID-19 vaccine

Pfizer’s CEO says the findings bring us closer to a breakthrough in the fight against the coronavirus pandemic. But critics warn that the study still hasn’t been peer-reviewed and safety data has yet to be released.
A researcher holds up an mRNA type vaccine candidate for the coronavirus disease (COVID-19) during a news conference. (Athit Perawongmetha/Reuters)

This week, as COVID-19 cases continue to climb across the country, there is a glimmer of hope for returning to normal life: a vaccine.

Pharmaceutical companies Pfizer and BioNTech say that results from a Phase 3 study of their vaccine candidate look promising and that immunity could last a year. 

Today, we hear from CBC science and technology reporter Emily Chung on what we know about the Pfizer-BioNTech vaccine that early results show is 90 per cent effective in preventing COVID-19.